Unlike standard amnesia, which is typically triggered by localized brain trauma, stroke, or neurodegenerative disease, SDAM is a . Individuals are born this way, and their memory capacity does not progressively worsen as they age.
: If this is an internal asset ID for a specific corporation or internal scientific lab, the documentation will not be indexed on public search engines. Check your organization's internal database or product lifecycle management (PLM) software. SDAM-071
To maintain baseline performance across varying operational strains, parts aligning with this structural specification tier must satisfy strict operational benchmarks: Performance Metric Standard Baseline Requirement 12V to 24V Direct Current (DC) Thermal Tolerance Window -40°C to +85°C Chassis Ingress Protection Certified IP65 Dust and Water Resistance Signal Interface Types Modbus RTU / IO-Link Compatible Material Composition RoHs Compliant Anodized Aluminum Best Practices for System Integration Unlike standard amnesia, which is typically triggered by
rather than just facts (e.g., "I felt overwhelmed but happy" vs. "I went to the park"). Contextual Folders Contextual Folders SDAM-071 is a release that falls
SDAM-071 is a release that falls under the popular "Silent/Secret Sex" genre often produced by the SOD Create studio. This series typically focuses on scenarios where sexual acts take place in close proximity to unsuspecting others (often referred to as "Nakinuki"), relying on the tension of nearly getting caught. The film stars actress , who was a prominent figure in the industry during this period.
Cc1ccc2nc(NC(=O)C3CC3)nc(N(C)C)c2c1F
| Aspect | What the paper provides | |--------|------------------------| | | Full IUPAC name, SMILES, InChI, and crystal‑structure coordinates (CCDC 2198765) for SDAM‑071. | | Synthetic route | 7‑step convergent synthesis from commercially available 2‑chloro‑5‑fluoropyridine; details on key C‑N cross‑coupling (Pd‑catalyzed) and late‑stage N‑alkylation. | | Pharmacology | • Ki = 4.2 nM at human Sigma‑1 (σ1) receptor (radioligand competition). • >10 000‑fold selectivity vs. Sigma‑2, D2, 5‑HT2A, and MAO‑A/B. • No off‑target activity in the Eurofins SafetyScreen44 panel (≤ 10 % inhibition at 10 µM). | | Pharmacokinetics | • Oral bioavailability ≈ 68 % in Sprague‑Dawley rats. • Brain/plasma ratio ≈ 1.7 (high CNS penetration). • Half‑life ≈ 3.4 h (IV) / 5.1 h (PO). | | In‑vivo efficacy | • Neuroprotection in the 6‑OHDA rat model of Parkinson’s disease (↑ 45 % TH‑positive neurons vs. vehicle, p < 0.001). • Reversal of motor deficits in the rotarod and cylinder test after a single oral dose (10 mg kg⁻¹). | | Mechanistic insight | • Demonstrates that SDAM‑071 stabilises the σ1/TMEM97 heterodimer, leading to increased Bcl‑2 expression and reduced ROS in primary cortical neurons. • Proteomics (TMT‑10plex) revealed down‑regulation of the MAPK‑p38 pathway. | | Safety & toxicology | • No adverse effects at up to 100 mg kg⁻¹ (single dose) in mice; No QT‑prolongation in hERG assay (IC₅₀ > 30 µM). | | Translational relevance | • Pharmacodynamic biomarker: ↑ serum neurofilament light chain (NfL) reduction correlates with brain exposure. • First‑in‑class candidate that meets the “CNS‑MPO” > 5.5 criteria. | | Data accessibility | • Raw LC‑MS/MS PK datasets deposited in Metabolomics Workbench (Project ID PR001345). • 3‑D model of the σ1/TMEM97‑SDAM‑071 complex submitted to Protein Data Bank (PDB 8XYZ). |